NASDAQ:KLDO - Kaleido Biosciences Stock Price, News & Analysis

$9.07
+0.12 (+1.34 %)
(As of 08/20/2019 04:00 PM ET)
Today's Range
$8.91
Now: $9.07
$9.9103
50-Day Range
$6.70
MA: $8.44
$11.35
52-Week Range
$6.23
Now: $9.07
$19.00
Volume69,028 shs
Average Volume67,064 shs
Market Capitalization$270.59 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kaleido BioSciences, Inc. develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KLDO
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees118
Market Cap$270.59 million
Next Earnings Date11/7/2019 (Estimated)
OptionableNot Optionable

Receive KLDO News and Ratings via Email

Sign-up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter.


Kaleido Biosciences (NASDAQ:KLDO) Frequently Asked Questions

What is Kaleido Biosciences' stock symbol?

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences Inc (NASDAQ:KLDO) released its quarterly earnings results on Thursday, August, 1st. The company reported ($0.83) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.74) by $0.09. View Kaleido Biosciences' Earnings History.

When is Kaleido Biosciences' next earnings date?

Kaleido Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Kaleido Biosciences.

What price target have analysts set for KLDO?

5 brokerages have issued twelve-month price targets for Kaleido Biosciences' stock. Their predictions range from $15.00 to $20.00. On average, they anticipate Kaleido Biosciences' stock price to reach $17.70 in the next year. This suggests a possible upside of 95.1% from the stock's current price. View Analyst Price Targets for Kaleido Biosciences.

What is the consensus analysts' recommendation for Kaleido Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kaleido Biosciences.

Has Kaleido Biosciences been receiving favorable news coverage?

Media stories about KLDO stock have trended positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kaleido Biosciences earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for Kaleido Biosciences.

Are investors shorting Kaleido Biosciences?

Kaleido Biosciences saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 741,200 shares, an increase of 9.9% from the June 30th total of 674,300 shares. Based on an average trading volume of 59,100 shares, the short-interest ratio is presently 12.5 days. Currently, 8.4% of the company's stock are short sold. View Kaleido Biosciences' Current Options Chain.

Who are some of Kaleido Biosciences' key competitors?

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Micron Technology (MU), NVIDIA (NVDA), Sequential Brands Group (SQBG), TG Therapeutics (TGTX), Cross Timbers Royalty Trust (CRT), Cara Therapeutics (CARA), HEXO (HEXO), Intel (INTC), JD.Com (JD) and Prospect Capital (PSEC).

Who are Kaleido Biosciences' key executives?

Kaleido Biosciences' management team includes the folowing people:
  • Mr. Michael W. Bonney, Exec. Chair (Age 61)
  • Ms. Alison Lawton, CEO, Pres & Director (Age 58)
  • Dr. Noubar B. Afeyan Ph.D., Co-Founder & Director (Age 56)
  • Dr. Geoffrey von Maltzahn Ph.D., Co-Founder & Director (Age 38)
  • Mr. Joshua T. Brumm, COO & CFO (Age 41)

When did Kaleido Biosciences IPO?

(KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

When does Kaleido Biosciences' lock-up period expire?

Kaleido Biosciences' lock-up period expires on Tuesday, August 27th. Kaleido Biosciences had issued 5,000,000 shares in its IPO on February 28th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. After the expiration of Kaleido Biosciences' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are Kaleido Biosciences' major shareholders?

Kaleido Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Artal Group S.A. (3.02%), BlackRock Inc. (0.82%), Vanguard Group Inc. (0.31%), Victory Capital Management Inc. (0.30%), Charles Schwab Investment Management Inc. (0.10%) and Menta Capital LLC (0.05%). Company insiders that own Kaleido Biosciences stock include Michael W Bonney and Ventures Fund V LP Flagship. View Institutional Ownership Trends for Kaleido Biosciences.

Which major investors are selling Kaleido Biosciences stock?

KLDO stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A. and Victory Capital Management Inc.. View Insider Buying and Selling for Kaleido Biosciences.

Which major investors are buying Kaleido Biosciences stock?

KLDO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Charles Schwab Investment Management Inc., Menta Capital LLC, Northern Trust Corp and Tower Research Capital LLC TRC . Company insiders that have bought Kaleido Biosciences stock in the last two years include Michael W Bonney and Ventures Fund V LP Flagship. View Insider Buying and Selling for Kaleido Biosciences.

How do I buy shares of Kaleido Biosciences?

Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kaleido Biosciences' stock price today?

One share of KLDO stock can currently be purchased for approximately $9.07.

How big of a company is Kaleido Biosciences?

Kaleido Biosciences has a market capitalization of $270.59 million. Kaleido Biosciences employs 118 workers across the globe.View Additional Information About Kaleido Biosciences.


MarketBeat Community Rating for Kaleido Biosciences (NASDAQ KLDO)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  21 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  60
MarketBeat's community ratings are surveys of what our community members think about Kaleido Biosciences and other stocks. Vote "Outperform" if you believe KLDO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KLDO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel